NCT01668797View on ClinicalTrials.gov

Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia

PHASE3CompletedINTERVENTIONAL
Enrollment

524

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

January 31, 2015

Study Completion Date

February 28, 2015

Conditions
Acute Schizophrenia
Interventions
DRUG

Brexpiprazole

Brexpiprazole tablets 1 to 4 mg /day

DRUG

Placebo

Placebo comparator for 52 weeks

Trial Locations (49)

11000

Belgrade

11040

Belgrade

15586

Kota Bharu

20070

Denizli

21000

Novi Sad

21280

Diyarbakır

23230

Richmond

23330

Novi Kneževac

33613

Tampa

34000

Kragujevac

38119

Memphis

41380

Kocaeli

43000

Kajang

56000

Kuala Lumpur

59100

Kuala Lumpur

60169

Hoffman Estates

61036

Kharkiv

61068

Kharkiv

63141

St Louis

63304

Saint Charles

65014

Odesa

69101

North Platte

73488

Kherson,Vil. Stepanivka

75231

Dallas

79021

Lviv

88815

Sabak Bernam

89102

Las Vegas

90703

Cerritos

92102

San Diego

92103

San Diego

92805

Anaheim

92845

Garden Grove

95006

Simferopol

110069

Piteşti

130086

Târgovişte

200473

Craiova

310022

Arad

500123

Brasov

620165

Focşani

700282

Iași

00000

Barranquilla

Bello

Bogotá

Pereira

00918

San Juan

00927

San Juan

041914

Bucharest

02660

Kyiv

04080

Kyiv

All Listed Sponsors
collaborator

Quintiles, Inc.

INDUSTRY

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT01668797 - Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia | Biotech Hunter | Biotech Hunter